Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of December 2021, with a specific reporting date of December 13, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| 2021-12-09 | Ordinary Shares (25p each) | £16.0118 | 144 shares (aggregate) | London Stock Exchange (XLON) |
Note: The aggregate volume of 144 shares is derived from the sum of individual transactions listed in the filing.
Material Changes
This filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It is a routine regulatory disclosure of executive share acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The transactions were executed under the Company's Share Reward Plan, involving both partnership shares and matching shares.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs and PCAs on December 9, 2021, against the company's insider trading logs.
- Confirm the transaction price of £16.0118 aligns with the market price on the London Stock Exchange for that date.
- Review the specific roles of the individuals listed (e.g., CEO, President of Vaccines, Chief Strategy Officer) to assess the breadth of executive participation in the Share Reward Plan.
- Note that this filing does not provide data on the company's overall financial performance for the period.